跳到主要內容區塊
:::首頁 > 就醫指南 > 醫師專長介紹

王俊興醫師

引用
現在日期 2022/06/27
科別分類符號 醫師個人簡介
主治專長
糖尿病、一般內科學
專業經驗
中華民國糖尿病學會副祕書長
重要經歷/進修訓練
臺中榮總內分泌新陳代謝科主治醫師(2009/05~迄今)
臺中榮總內分泌新陳代謝科總醫師(2006/09-2009/04)
臺中榮總內科部住院醫師(2003/05-2006/08)
學歷
台北醫學大學醫學系畢業
國立陽明大學臨床醫學研究所博士班畢業
專科證照
中華民國內科醫學會內科專科醫師
中華民國內分泌糖尿病學會專科醫師
中華民國糖尿病衛教學會合格衛教人員
教師資格
國立陽明大學內科 兼任助理教授
國立中興大學生物醫學研究所 兼任助理教授
研究興趣
糖尿病、肥胖、心血管疾病相關併發症
代表作
1. Wang JS*, Lee IT, Lee WJ, Lin SD, Su SL, Tu ST, Lin SY, Sheu WH. The dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs. Ther Adv Chronic Dis. 2021; 12: 20406223211033674.
2. Wang JS, Liu WJ, Lee CL*. HbA1c trajectory and cardiovascular outcomes: An analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Ther Adv Chronic Dis. 2021; 12: 20406223211026391.
3. Wang JS, Lo SH, Yeh YP, Hwu CM, Huang CN, Hsieh CH, Sheu WH*. Distinct associations of self-monitoring of blood glucose with glycemic control and hypoglycemia between groups of recently diagnosed and long-term follow-up type 2 diabetes: the Taiwan Diabetes Registry. Int J Clin Pract. 2021 May 28:e14410. Online ahead of print.
4. Wang JS*, Lee IT, Lee WJ, Lin SY, Lee WL, Liang KW, Sheu WH. Postchallenge glucose increment was associated with hemoglobin glycation index in subjects with no history of diabetes. J Investig Med. 2021; 69: 1044-1049.
5. Lee CL, Liu WJ, Wang JS*. Associations of low-carbohydrate and low-fat intakes with all-cause mortality in subjects with prediabetes with and without insulin resistance. Clin Nutr. 2021; 40: 3601-3607.
6. Lee CL, Liu WJ, Wang JS*. Association of diurnal calorie trajectory with all-cause mortality: Findings from the National Health and Nutrition Examination Survey. Clin Nutr. 2021; 40: 1920-1925.
7. Lee CL, Liu WJ, Wang JS*. Effect of low-protein intake on all-cause mortality in subjects with an estimated glomerular filtration rate higher than 60 mL/min/1.73 m2 with or without albuminuria. Int J Clin Pract. 2020; 74: e13505.
8. Wang JS, Chen H, Tang F, Sheu WH*. Associations of fear of hypoglycemia with second-line use of insulin secretagogues or insulin and subsequent glycemic control in patients with type 2 diabetes: An analysis using data from the DISCOVER study. Int J Clin Pract. 2020; 74: e13485.
9. Lee CL, Wang JS*. Systolic blood pressure trajectory and cardiovascular outcomes: An analysis using data in the Systolic Blood Pressure Intervention Trial. Int J Clin Pract. Int J Clin Pract. 2020; 74: e13450.
10. Lee CL, Wang JS*. Effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease stages 3-5: a retrospective cohort study. Sao Paulo Med J. 2019; 137: 523-529.
11. Wang JS, Wu YL, Shin SJ, Tien KJ, Chin MC, Hwu CM*. Hospitalization in patients with type 2 diabetes mellitus in Taiwan: A nationwide population-based observational study. J Formos Med Assoc. 2019; 118 Suppl 2: S90-S95.
12. Li YH, Sheu WH, Lee WJ, Lee IT, Lin SY, Lee WL, Liang KW, Wang JS*. Testing for HbA1c, in addition to the oral glucose tolerance test, in screening for abnormal glucose regulation helps to reveal patients with early β-cell function impairment. Clin Chem Lab Med. 2018; 56: 1345-1352.
13. Wang JS, Sheu WH, Lee WJ, Lee IT, Lin SY, Lee WL, Liang KW, Lin SJ*. Levels of serum high mobility group box 1 were independently associated with cardiovascular risk in patients undergoing coronary angiography. Clin Chim Acta. 2018; 483: 130-134.
14. Lee CL, Sheu WH, Lee IT, Lin SY, Liang WM, Wang JS*, Li YF*. Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes. Diabetes Metab. 2018; 44: 121-128.
15. Wang JS, Lee WJ, Lee IT, Lin SY, Lee WL, Liang KW, Lin SJ*, Sheu WH*. Negative association between serum aryl hydrocarbon receptor concentrations and β-cell function in patients with no history of diabetes undergoing coronary angiography. J Diabetes. 2018; 10: 958-964.
16. Wang JS, Hung YJ, Lu YC, Tsai CL, Yang WS, Lee TI, Hsiao YC, Sheu WH*. Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018; 138: 119-127.
回頂端